Michael Grissinger - 16 May 2022 Form 3 Insider Report for Aprea Therapeutics, Inc. (APRE)

Role
Director
Signature
/s/ Scott M. Coiante, attorney-in-fact
Issuer symbol
APRE
Transactions as of
16 May 2022
Net transactions value
$0
Form type
3
Filing time
26 May 2022, 16:15:59 UTC
Next filing
01 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding APRE Stock Option (right to buy) 16 May 2022 Common Stock 72,638 $0.4400 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Remarks:

Exhibit 24 - Power of Attorney